JP2023526224A5 - - Google Patents

Info

Publication number
JP2023526224A5
JP2023526224A5 JP2022568713A JP2022568713A JP2023526224A5 JP 2023526224 A5 JP2023526224 A5 JP 2023526224A5 JP 2022568713 A JP2022568713 A JP 2022568713A JP 2022568713 A JP2022568713 A JP 2022568713A JP 2023526224 A5 JP2023526224 A5 JP 2023526224A5
Authority
JP
Japan
Prior art keywords
seq
sequence
cancer
nos
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526224A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032078 external-priority patent/WO2021231639A1/en
Publication of JP2023526224A publication Critical patent/JP2023526224A/ja
Publication of JP2023526224A5 publication Critical patent/JP2023526224A5/ja
Pending legal-status Critical Current

Links

JP2022568713A 2020-05-12 2021-05-12 がんを治療するための、がん治療薬との組合せでの多量体抗dr5結合分子の使用 Pending JP2023526224A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063023635P 2020-05-12 2020-05-12
US63/023,635 2020-05-12
US202063078747P 2020-09-15 2020-09-15
US63/078,747 2020-09-15
US202063114990P 2020-11-17 2020-11-17
US63/114,990 2020-11-17
US202063131698P 2020-12-29 2020-12-29
US63/131,698 2020-12-29
US202163136156P 2021-01-11 2021-01-11
US63/136,156 2021-01-11
PCT/US2021/032078 WO2021231639A1 (en) 2020-05-12 2021-05-12 Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer

Publications (2)

Publication Number Publication Date
JP2023526224A JP2023526224A (ja) 2023-06-21
JP2023526224A5 true JP2023526224A5 (cg-RX-API-DMAC7.html) 2024-05-24

Family

ID=78524993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568713A Pending JP2023526224A (ja) 2020-05-12 2021-05-12 がんを治療するための、がん治療薬との組合せでの多量体抗dr5結合分子の使用

Country Status (11)

Country Link
US (1) US20230174660A1 (cg-RX-API-DMAC7.html)
EP (1) EP4149553A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023526224A (cg-RX-API-DMAC7.html)
KR (1) KR20230010221A (cg-RX-API-DMAC7.html)
CN (1) CN115697419A (cg-RX-API-DMAC7.html)
AU (1) AU2021271647A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022145A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173919A1 (cg-RX-API-DMAC7.html)
IL (1) IL297619A (cg-RX-API-DMAC7.html)
MX (1) MX2022014259A (cg-RX-API-DMAC7.html)
WO (1) WO2021231639A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
WO2022154664A1 (en) * 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
EP4529455A1 (en) * 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
WO2024148339A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. Use of a multimeric anti-dr5 antibody for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100847010B1 (ko) * 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (dr5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
US8193161B2 (en) * 2008-06-09 2012-06-05 New York Medical College Compositions comprising cardiac stem cells overexpressing specific micrornas and methods of their use in repairing damaged myocardium
PT3247728T (pt) * 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
MX2018006333A (es) * 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
EP3759229A4 (en) * 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变

Similar Documents

Publication Publication Date Title
ES2387809T3 (es) Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
JP2021059564A (ja) 癌治療のための併用療法
JP2021514945A5 (cg-RX-API-DMAC7.html)
JP2008528486A5 (cg-RX-API-DMAC7.html)
JP2019503349A5 (cg-RX-API-DMAC7.html)
AU2021271647A1 (en) Use of a multimeric anti-DR5 binding molecule in combination with a cancer therapy for treating cancer
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2024509018A5 (cg-RX-API-DMAC7.html)
EP3347054A1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
CN108350080A (zh) 用于癌症的联合疗法
AU2020242144A1 (en) Combined pharmaceutical composition for treating small cell lung cancer
JP2023155262A (ja) プレクチン1結合抗体およびその使用
WO2022270524A1 (ja) 癌の治療及び/又は予防のための医薬品
JP2024515879A5 (cg-RX-API-DMAC7.html)
KR20100040884A (ko) 화학요법제와 조합하여 암을 치료하기 위한 이뮤노사이토킨
CN120437318A (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
CN101175495B (zh) 抗癌化合物的组合
CN120752053A (zh) 含抗tim-3抗体的药物组合
CN111065412B (zh) Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途
EP4406552A1 (en) Use of anti-cd40 antibody
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
HK40124723A (en) Combined use of an antibody-drug conjugate and an immune checkpoint inhibitor
TW202339796A (zh) 靶向egfr之癌症療法
Kreisl Neurologic complications of antitumor antibody therapies
TW201315461A (zh) 與放射線治療關聯之包含奧瑞布林(ombrabulin)及西妥昔單抗(cetuximab)之抗腫瘤組合